Sunrise Medical Technology Co., Ltd. signed an agreement to acquire 5.3% stake in ValueBiotech S.R.L. from Yimikang Tech.Group Co., Ltd. (SZSE:300249) for RMB 4.1 million on September 29, 2021. SunrisE shall pay the equity transfer price to Yimikang in RMB. Within 45 working days from the date of signing and taking effect of this agreement, Sunrise shall pay Yimikang not less than 50% of the equity transfer price; Within 10 working days after the completion of the registration procedures for domestic and overseas changes in the subject equity, SunrisE shall pay the remaining equity transfer payment to Yimikang. After the completion of this transaction, the company will no longer hold VALUEBIOTECH S.R.L equity, and VALUEBIOTECH S.R.L will no longer be a subsidiary of the company. As of September 28, 2021, the board of directors of Yimikang Tech.Group approved the transaction. ValueBiotech reported total assets as RMB 1.7 million, net assets as RMB 1.39 million, operating income as RMB 0.0012 million, total profit as RMB -0.6 million and net profit as RMB -0.6 million.